In a significant legal victory for Guardant Health, a U.S. jury has awarded the company $292.5 million after finding that their competitor, Natera, engaged in false advertising and unfair competition. The ruling stems from a lawsuit filed by Guardant in May 2021, which accused Natera of running a “campaign of misinformation” aimed at undermining Guardant’s Reveal cancer test. The jury’s decision, delivered in early November, sided entirely with Guardant on all claims made in the lawsuit, while dismissing all counterclaims from Natera, which is known for its Signatera cancer test.
Guardant’s Reveal test, launched in February 2021, is designed to detect residual and recurrent colorectal cancer in patients post-surgery, potentially guiding further treatment options like chemotherapy. The lawsuit alleges that Natera began targeting Guardant’s clients shortly after the Reveal’s introduction, attempting to persuade healthcare providers, including reputable institutions like the Mayo Clinic, to opt for Signatera instead. Central to the case were claims made in a promotional email from Natera, which warned against laboratories in the molecular residual disease market making “potentially misleading claims” without peer-reviewed evidence, although it did not explicitly name Guardant’s product.
The court documents indicate that Natera referenced data related to Guardant’s test in its marketing materials, which Guardant’s legal team argued was subject to peer review. The trial witnessed the presentation of allegations from Guardant alongside Natera’s counterclaims, with Natera seeking unspecified damages and injunctive relief. However, the jury ultimately sided with Guardant, determining that Natera’s actions constituted false advertising and awarding significant punitive damages.
The awarded sum includes $175.5 million in punitive damages, marking it as one of the largest false advertising verdicts recorded historically. This outcome has been highlighted by Guardant as a substantial affirmation of their product’s integrity and a condemnation of unfair marketing practices in the competitive landscape of cancer detection technologies. Natera, on the other hand, has expressed its disagreement with the verdict and plans to request an overturn of the ruling in court.
Despite the legal challenges, Natera ended the third quarter with a robust financial position, reporting $922.3 million in cash and investments, indicating that the company remains financially solvent despite the jury’s judgment. In a statement released following the trial, Natera clarified that its advertising campaign, which was discussed in the trial, only ran briefly in 2021 and emphasized that the case revolved around marketing practices rather than the validity or effectiveness of the Signatera test itself. The company asserted that critical evidence supporting its stance was excluded from the trial.
As the case evolves, the implications of this ruling extend beyond Guardant and Natera, potentially influencing how biotechnology firms navigate competitive advertising and market claims in a tightly regulated industry. The outcome also shines a spotlight on the broader challenges facing cancer testing providers, illustrating the complexities of proving product efficacy amidst aggressive messaging from rivals. With Guardant set to benefit from this verdict, the outcome could reshape the competitive strategies employed by firms in the cancer diagnostics arena moving forward.